StockMacro
Menu

Praxis Precision Medicines

$300.43 -14% in 6 monthsMarket cap $8.4B

PRAX on XNAS, Health Care, Praxis Precision Medicines, Inc., job postings

Measures activity, not value. Not investment advice.

Shares rose 83% in a year, but short interest is 15% of shares, up 7.3% on the prior report.

  • GoodInstitutional holders rose 9.8% to 335 from the quarter before
  • Watch59% of its 144 open job postings are sales and business development

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Industry
Pharmaceutical preparations (Health Care)
Employees
10,998
Website
praxismedicines.com
Listed
Nasdaq, US
Last results
9 Nov 2026
Next results
expected around 5 Jan 2027 (an estimate: a year ago it reported on 6 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $94.2M.
Quarter to 31 Dec 2021: revenue –, net income -$58.6MQuarter to 31 Mar 2022: revenue $0, net income -$68.7MQuarter to 31 Mar 2022: revenue $0, net income -$68.7MQuarter to 30 Jun 2022: revenue $0, net income -$60.2MQuarter to 30 Jun 2022: revenue $0, net income -$60.2MQuarter to 30 Sep 2022: revenue $0, net income -$43.9MQuarter to 30 Sep 2022: revenue $0, net income -$43.9MQuarter to 31 Dec 2022: revenue $0, net income -$41.2MQuarter to 31 Dec 2022: revenue $0, net income -$41.2MQuarter to 31 Mar 2023: revenue $683K, net income -$37.5MQuarter to 31 Mar 2023: revenue $683K, net income -$37.5MQuarter to 30 Jun 2023: revenue $781K, net income -$34.3MQuarter to 30 Jun 2023: revenue $781K, net income -$34.3MQuarter to 30 Sep 2023: revenue $468K, net income -$24.6MQuarter to 30 Sep 2023: revenue $468K, net income -$24.6MQuarter to 31 Dec 2023: revenue $515K, net income -$26.9MQuarter to 31 Dec 2023: revenue $515K, net income -$26.9MQuarter to 31 Mar 2024: revenue $431K, net income -$39.6MQuarter to 31 Mar 2024: revenue $431K, net income -$39.6MQuarter to 30 Jun 2024: revenue $357K, net income -$32.7MQuarter to 30 Jun 2024: revenue $357K, net income -$32.7MQuarter to 30 Sep 2024: revenue $302K, net income -$51.9MQuarter to 30 Sep 2024: revenue $302K, net income -$51.9MQuarter to 31 Dec 2024: revenue $7.5M, net income -$58.7MQuarter to 31 Dec 2024: revenue $7.5M, net income -$58.7MQuarter to 31 Mar 2025: revenue $0, net income -$69.3MQuarter to 31 Mar 2025: revenue $0, net income -$69.3MQuarter to 30 Jun 2025: revenue $0, net income -$71.1MQuarter to 30 Jun 2025: revenue $0, net income -$71.1MQuarter to 30 Sep 2025: revenue $0, net income -$73.9MQuarter to 30 Sep 2025: revenue $0, net income -$73.9MQuarter to 31 Dec 2025: revenue $0, net income -$88.9MQuarter to 31 Dec 2025: revenue $0, net income -$88.9MQuarter to 31 Mar 2026: revenue –, net income -$92.6MQuarter to 30 Jun 2026: revenue –, net income -$83.7MQuarter to 30 Sep 2026: revenue –, net income -$94.2M
31 Dec 2021RevenueNet incomeNet losstallest bar $94.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$94.2M
30 Jun 2026–-$83.7M
31 Mar 2026–-$92.6M
31 Dec 2025$0-$88.9M
30 Sep 2025$0-$73.9M
30 Jun 2025$0-$71.1M
31 Mar 2025$0-$69.3M
31 Dec 2024$7.5M-$58.7M
30 Sep 2024$302K-$51.9M
30 Jun 2024$357K-$32.7M
31 Mar 2024$431K-$39.6M
31 Dec 2023$515K-$26.9M
30 Sep 2023$468K-$24.6M
30 Jun 2023$781K-$34.3M
31 Mar 2023$683K-$37.5M
31 Dec 2022$0-$41.2M
30 Sep 2022$0-$43.9M
30 Jun 2022$0-$60.2M
31 Mar 2022$0-$68.7M
31 Dec 2021–-$58.6M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – $7.5M
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$359.4M -$273.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$12.81 -$12.96
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -44.8% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$228.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.3B $389.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$1.3B (net cash) -$389.2M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $45.06
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 6.7 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Praxis Precision MedicinesPRAX (this company) $8.4Bloss–––
Madrigal PharmaceuticalsMDGL $8.8Bloss6.2+93%-10.9%
Summit TherapeuticsSMMT $8.0Bloss–––
Spyre TherapeuticsSYRE $8.9Bloss–––
Protagonist TherapeuticsPTGX $7.9B23.214.4+164%62.0%
Rhythm PharmaceuticalsRYTM $7.8Bloss27.7+61%-69.0%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+9.8%

335 13F filers vs 305

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

34.6M shares held by 13F filers (30 Sep 2026) of 28.0M outstanding (4 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

15%

4.2M shares sold short (30 Oct 2026) of 28.0M outstanding (4 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.7

4.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+7.3%

3.9M shares sold short in the report before, 4.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

67%

67% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 63%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

144

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$280K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

30

30 articles in the last 7 days; its usual week has 8.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.5×

30 articles in the last 7 days; its usual week has 8.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Lobbying spend $160K, 4.0× a year earlier
  • New institutional positions 70, 2.7× a year earlier
  • New lobbying issue

Price $300.43 on 20 Nov 2026, +83% over 12 months (12-month range $164.09 to $386.33)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $3.6M in the last 12 months (the 12 months before: -$40.7M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 4 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.
Capital spending per quarter. Capital spending $245K in the latest quarter, +338% on a year earlier.
Institutional holders (13F filers). 335 13F filers reported holding it in the latest 13F quarter, +131% on a year earlier.
Lobbying spend. Lobbying spend: $280K published in the last 12 months, +87% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 70 vs usual 32.50 (2026-09-30); 2.7x the same period a year earlier
27 Oct 2026Sharp changeLobbying spend jump: lobbying spend jump, 160K vs usual 40K (2026-09-30); 4.0x the same period a year earlier
21 Oct 2026Sharp changeLobbying on a new issue: lobbying on a new issue: HCR (2026-09-30)
17 Aug 2026Lobbying filingnew lobbying registration (BALLARD PARTNERS)
2 Jul 20268-K and other filingsChanged its auditor
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 68 vs usual 32.50 (2026-03-31); 2.1x the same period a year earlier
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 93 vs usual 30 (2025-12-31); 2.9x the same period a year earlier
13 Jan 2026Sharp changeShort interest spike: short interest spike, 3.8M vs usual 2.1M (2025-12-31); 2.0x the same period a year earlier
8 Jan 20268-K and other filingsDirector or officer change
8 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Dec 2025Sharp changeShort interest spike: short interest spike, 3.7M vs usual 2.1M (2025-12-15); 2.4x the same period a year earlier
16 Dec 2025Sharp changeShort interest spike: short interest spike, 3.6M vs usual 2.0M (2025-11-28); 2.4x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 3.6M vs usual 2.0M (2025-11-14); 2.4x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 3.1M vs usual 1.9M (2025-10-31); 1.8x the same period a year earlier
14 Oct 2025Sharp changeShort interest spike: short interest spike, 2.6M vs usual 1.9M (2025-09-30); 1.5x the same period a year earlier
15 Oct 20248-K and other filingsDirector or officer change
15 Oct 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Jun 20248-K and other filingsDirector or officer change
6 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 56 vs usual 14 (2024-03-31); 5.1x the same period a year earlier
11 Jan 20248-K and other filingsA major agreement ended
16 Jun 20238-K and other filingsA major agreement ended
28 Mar 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 109K)
21 Mar 20238-K and other filingsDirector or officer change
21 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Feb 2023Lobbying filingnew lobbying registration (THE KPM GROUP DC LLC)
15 Feb 2023Sharp changeFirst lobbying registration: first lobbying registration: PRAXIS PRECISION MEDICINES: new lobbying registration (THE KPM GROUP DC LLC)
12 Aug 20228-K and other filingsDirector or officer change
26 Jul 20228-K and other filingsDirector or officer change
19 Jul 2022Sharp changeShort interest spike: short interest spike, 3.6M vs usual 1.6M (2022-06-30); 2.9x the same period a year earlier
28 Jun 2022Sharp changeShort interest spike: short interest spike, 2.9M vs usual 1.5M (2022-06-15); 2.0x the same period a year earlier
14 Jun 2022Sharp changeShort interest spike: short interest spike, 4.1M vs usual 1.5M (2022-05-31); 3.2x the same period a year earlier
14 Jun 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 113K)
31 May 2022Sharp changeShort interest spike: short interest spike, 3.8M vs usual 1.5M (2022-05-13); 2.4x the same period a year earlier
23 May 20228-K and other filingsDirector or officer change
23 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 May 2022Sharp changeShort interest spike: short interest spike, 3.6M vs usual 1.5M (2022-04-29); 1.9x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 3.2M vs usual 1.5M (2022-04-14); 1.4x the same period a year earlier
12 Apr 2022Sharp changeShort interest spike: short interest spike, 3.1M vs usual 1.5M (2022-03-31); 1.5x the same period a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 3.2M vs usual 1.5M (2022-03-15); 3.6x the same period a year earlier
15 Mar 2022Sharp changeShort interest spike: short interest spike, 2.7M vs usual 1.5M (2022-02-28); 3.4x the same period a year earlier
1 Mar 2022Sharp changeShort interest spike: short interest spike, 2.4M vs usual 1.4M (2022-02-15); 2.7x the same period a year earlier
Insider net buying (open market)
Month from 1 Jun 2022: $131K published
Month from 1 Mar 2023: $109K published
Month from 1 Jun 2023: $11K published
Month from 1 Oct 2023: $25K published
Month from 1 Nov 2024: -$1.1M published
Month from 1 Oct 2025: -$33.2M published
Month from 1 Nov 2025: -$7.5M published
Month from 1 Jun 2026: -$3.6M published
H-1B/E-3 applications certified
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Jan 2024: 1 published
Quarter from 1 Jul 2024: 1 published
Quarter from 1 Jul 2026: 3 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Mar 2022: $0; public on 12 May 2023
Quarter ended 30 Jun 2022: $0; public on 10 Aug 2023
Quarter ended 30 Sep 2022: $0; public on 8 Nov 2023
Quarter ended 31 Dec 2022: $0; public on 6 Mar 2024
Quarter ended 31 Mar 2023: $683K; public on 12 May 2023
Quarter ended 30 Jun 2023: $781K; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $468K; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $515K; public on 6 Mar 2024
Quarter ended 31 Mar 2024: $431K, -37% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $357K, -54% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $302K, -35% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $7.5M, +1349% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $0, -100% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $0, -100% on a year earlier; public on 20 Feb 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $289K, +7125% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $110K, +69% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $45K, -90% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $50K; public on 6 Mar 2024
Quarter ended 30 Sep 2024: $0; public on 6 Nov 2025
Quarter ended 31 Dec 2024: $0, -100% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $0; public on 8 May 2026
Quarter ended 30 Jun 2025: $56K; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $62K; public on 8 May 2026
Quarter ended 30 Jun 2026: $245K, +338% on a year earlier; public on 7 Aug 2026
Institutional holders (13F filers)
31 Dec 2021 report: 91; public on 14 Feb 2022
31 Mar 2022 report: 101; public on 16 May 2022
30 Jun 2022 report: 89; public on 15 Aug 2022
30 Sep 2022 report: 100; public on 14 Nov 2022
31 Dec 2022 report: 100; public on 14 Feb 2023
31 Mar 2023 report: 84; public on 15 May 2023
30 Jun 2023 report: 75; public on 14 Aug 2023
30 Sep 2023 report: 70; public on 14 Nov 2023
31 Dec 2023 report: 57; public on 14 Feb 2024
31 Mar 2024 report: 108; public on 15 May 2024
30 Jun 2024 report: 112; public on 14 Aug 2024
30 Sep 2024 report: 131; public on 14 Nov 2024
31 Dec 2024 report: 161; public on 14 Feb 2025
31 Mar 2025 report: 147; public on 15 May 2025
30 Jun 2025 report: 138; public on 14 Aug 2025
30 Sep 2025 report: 145; public on 14 Nov 2025
31 Dec 2025 report: 238; public on 17 Feb 2026
31 Mar 2026 report: 280; public on 15 May 2026
30 Jun 2026 report: 305; public on 14 Aug 2026
30 Sep 2026 report: 335; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2023: $40K published
Quarter from 1 Jul 2023: $40K published
Quarter from 1 Oct 2023: $40K published
Quarter from 1 Jan 2024: $40K published
Quarter from 1 Apr 2024: $30K published
Quarter from 1 Jul 2024: $30K published
Quarter from 1 Oct 2024: $30K published
Quarter from 1 Jan 2025: $30K published
Quarter from 1 Apr 2025: $40K published
Quarter from 1 Jul 2025: $40K published
Quarter from 1 Oct 2025: $40K published
Quarter from 1 Jan 2026: $40K published
Quarter from 1 Apr 2026: $40K published
Quarter from 1 Jul 2026: $40K published
Quarter from 1 Oct 2026: $160K published

What is unusual now

  • Made public in the last 90 days: it reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year; it also saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year. 3 sharp changes in all. Two or more unrelated kinds of activity agreed on 17 Nov 2026.
  • Lobbying spend jump: reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year Public on 21 Oct 2026.
  • Many funds opening a new position: saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year Public on 16 Nov 2026.
  • Lobbying on a new issue: lobbying on a new issue Public on 21 Oct 2026.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 28 insider trades

No trades in the last 90 days; the latest was filed 26 Jun 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
26 Jun 2026Jill DeSimoneDirectorSellplanned in advance (10b5-1); after exercising options11,600$311.32$3.6MForm 4
21 Nov 2025Alex NemiroffGeneral Counsel and SecretarySellafter exercising options25,130$193.08$4.9MForm 4
21 Nov 2025Lauren MastrocolaPrincipal Accounting OfficerSellafter exercising options13,600$192.08$2.6MForm 4
17 Oct 2025Phillip Gross and 2 others10% ownerSell313,910$105.76$33.2MForm 4
15 Nov 2024Lauren MastrocolaPrincipal Accounting OfficerSellafter exercising options5,188$81.78$424KForm 4
15 Nov 2024Alex NemiroffGeneral Counsel and SecretarySellafter exercising options8,239$80.20$661KForm 4
10 Oct 2023Jill DeSimoneDirectorBuy14,500$1.75$25KForm 4
27 Jun 2023Marcio SouzaChief Executive OfficerBuy10,000$1.06$11KForm 4

335 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 69 opened a position, 41 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Janus Henderson Group Ltd.3.4M12.3%$1.0B
FMR LLC (Fidelity)2.6M9.44%$768.2M+321K+14%
BlackRock, Inc.2.2M7.99%$650.3M-60K-2.6%
Perceptive Advisors LLC2.0M7.24%$589.7M-11K-0.6%
Baker Bros. Advisors LP1.8M6.27%$510.6MNo change
Orbis Allan Gray Ltd1.4M4.87%$396.1M-170K-11%
Vanguard Portfolio Management LLC1.3M4.67%$380.0M-30K-2.3%
Vanguard Capital Management LLC1.2M4.40%$357.9M-6,269-0.5%
State Street Corp1.0M3.74%$304.1M+18K+1.8%
Adage Capital Partners GP, L.L.C.982K3.51%$285.8M-34K-3.3%

Company events

All 24 company events

In 12 months: 1 director or officer change, 1 auditor change. Results releases and routine reports are left out.

FiledWhat happenedSource
2 Jul 2026Changed its auditor8-K
8 Jan 2026Director or officer change8-K
15 Oct 2024Director or officer change8-K
6 Jun 2024Director or officer changeSame filing: shareholder vote results8-K
11 Jan 2024A major agreement ended8-K
7 Dec 2023Signed a major agreement8-K
16 Jun 2023A major agreement ended8-K
21 Mar 2023Director or officer change8-K

144 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 59%, Marketing & communications 11%, Program & project management 11%, Legal, policy & compliance 7%.

PostedJobLocation
17 Nov 2026Senior Manager, Regulatory CMCLegal, policy & complianceUnited States - Remote
13 Nov 2026Director, Commercial Manufacturing OperationsManufacturing & productionUnited States - Remote
13 Nov 2026Manager Commercial Meetings & Marketing OperationsMarketing & communicationsUnited States - Remote
12 Nov 2026Medical Science Liaison - Pacific NorthwestProgram & project managementUnited States - Remote
12 Nov 2026Manager CMC Materials ManagementSupply chain & procurementIndia - REMOTE
6 Nov 2026Promotional Review and Production SpecialistManufacturing & productionUnited States - Remote
4 Nov 2026Director, CMC External ManufacturingManufacturing & productionUnited States - Remote
4 Nov 2026Intern, Non-Clinical SafetyUnited States - Remote

Reported lobbying spend: $160K in Q3 2026, $40K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
11 Jul 2026NewBallard Partnersfor Praxis Precision Medicines, Inc.Engagement and strategy for the FDA and HHS related to product pipeline.Health issuesFiling
1 Jan 2023NewThe KPM Group DC LLCfor Praxis Precision MedicinesRare disease drug development Orphan Drug Act Orphan Drug Tax Credit Priority Review Voucher Expedited approval pathways Patient-focused drug development Neurology Drug ProgramHealth issues, PharmacyFiling

The 5 newest of 292 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Nov 2026confirmed

Confirmed across sources Institutional holdings and Lobbying

Praxis Precision Medicines (PRAX): reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year, while it saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year. Two unrelated kinds of activity within 27 days.

  • Lobbying: Lobbying on a new issue, became public on 21 Oct 2026
  • Lobbying: Lobbying spend jump, became public on 21 Oct 2026
  • Institutional holdings: Many funds opening a new position, became public on 16 Nov 2026
2024-09-30: $30K2024-12-31: $30K2025-03-31: $40K2025-06-30: $40K2025-09-30: $40K2025-12-31: $40K2026-03-31: $40K2026-06-30: $40K2026-09-30: $160K
The quarter ended 30 Sep 2026 against the 8 quarters before it. this quarterearliernormal: $40K
See the evidence (3 changes)

Lobbying: Lobbying on a new issue became public on 21 Oct 2026

Praxis Precision Medicines lobbying on a new issue.

New
['HCR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
9641691

Lobbying: Lobbying spend jump became public on 21 Oct 2026

Praxis Precision Medicines reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year.

This period
$160K (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$40K
Typical spread (median absolute deviation)
$0
How far from its usual level
+6.0
Same quarter last year
$40K
History used
1,279 days
2024-09-30: $30K2024-12-31: $30K2025-03-31: $40K2025-06-30: $40K2025-09-30: $40K2025-12-31: $40K2026-03-31: $40K2026-06-30: $40K2026-09-30: $160K
the quarter ended 30 Sep 20268 earlier quartersnormal: $40K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

Praxis Precision Medicines saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year.

This period
70 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
32.5
Typical spread (median absolute deviation)
7
How far from its usual level
+3.6
Same quarter last year
26
History used
2,099 days
2024-09-30: 282024-12-31: 322025-03-31: 332025-06-30: 252025-09-30: 262025-12-31: 932026-03-31: 682026-06-30: 552026-09-30: 70
the quarter ended 30 Sep 20268 earlier quartersnormal: 32.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

14 Jun 2022confirmed

Confirmed across sources Insiders and Short interest and volume

Praxis Precision Medicines (PRAX): had 3 insiders buy $113K of its shares on the open market within 30 days (3 filings), while it had 4.1M shares sold short in the 31 May 2022 report, 3.2× the same report last year. Two unrelated kinds of activity within 63 days.

  • Short interest and volume: Short interest spike, became public on 11 May 2022
  • Short interest and volume: Short interest spike, became public on 25 May 2022
  • Insiders: Clustered insider buying, became public on 14 Jun 2022
  • Short interest and volume: Short interest spike, became public on 10 Jun 2022
  • Short interest and volume: Short interest spike, became public on 28 Jun 2022
  • Short interest and volume: Short interest spike, became public on 13 Jul 2022
2021-05-14: 1.6M2021-05-28: 1.3M2021-06-15: 1.5M2021-06-30: 1.3M2021-07-15: 1.3M2021-07-30: 1.4M2021-08-13: 1.3M2021-08-31: 1.2M2021-09-15: 1.4M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.5M2021-11-15: 1.5M2021-11-30: 1.5M2021-12-15: 1.5M2022-01-14: 1.8M2022-01-31: 2.0M2022-02-15: 2.4M2022-02-28: 2.7M2022-03-15: 3.2M2022-03-31: 3.1M2022-04-14: 3.2M2022-04-29: 3.6M2022-05-13: 3.8M2022-05-31: 4.1M
The 31 May 2022 report against the 24 reports before it. this reportearliernormal: 1.5M
See the evidence (6 changes)

Short interest and volume: Short interest spike became public on 11 May 2022

Praxis Precision Medicines had 3.6M shares sold short in the 29 Apr 2022 report, 1.9× the same report last year.

This period
3.6M (the 29 Apr 2022 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
233K
How far from its usual level
+5.9
Same report last year
1.8M
History used
546 days
2021-04-15: 2.3M2021-04-30: 1.8M2021-05-14: 1.6M2021-05-28: 1.3M2021-06-15: 1.5M2021-06-30: 1.3M2021-07-15: 1.3M2021-07-30: 1.4M2021-08-13: 1.3M2021-08-31: 1.2M2021-09-15: 1.4M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.5M2021-11-15: 1.5M2021-11-30: 1.5M2021-12-15: 1.5M2022-01-14: 1.8M2022-01-31: 2.0M2022-02-15: 2.4M2022-02-28: 2.7M2022-03-15: 3.2M2022-03-31: 3.1M2022-04-14: 3.2M2022-04-29: 3.6M
the 29 Apr 2022 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 May 2022

Praxis Precision Medicines had 3.8M shares sold short in the 13 May 2022 report, 2.4× the same report last year.

This period
3.8M (the 13 May 2022 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
233K
How far from its usual level
+6.6
Same report last year
1.6M
History used
560 days
2021-04-30: 1.8M2021-05-14: 1.6M2021-05-28: 1.3M2021-06-15: 1.5M2021-06-30: 1.3M2021-07-15: 1.3M2021-07-30: 1.4M2021-08-13: 1.3M2021-08-31: 1.2M2021-09-15: 1.4M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.5M2021-11-15: 1.5M2021-11-30: 1.5M2021-12-15: 1.5M2022-01-14: 1.8M2022-01-31: 2.0M2022-02-15: 2.4M2022-02-28: 2.7M2022-03-15: 3.2M2022-03-31: 3.1M2022-04-14: 3.2M2022-04-29: 3.6M2022-05-13: 3.8M
the 13 May 2022 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Insiders: Clustered insider buying became public on 14 Jun 2022

Praxis Precision Medicines had 3 insiders buy $113K of its shares on the open market within 30 days (3 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$113K
Window
15 May 2022 to 14 Jun 2022

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 10 Jun 2022

Praxis Precision Medicines had 4.1M shares sold short in the 31 May 2022 report, 3.2× the same report last year.

This period
4.1M (the 31 May 2022 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
233K
How far from its usual level
+7.5
Same report last year
1.3M
History used
578 days
2021-05-14: 1.6M2021-05-28: 1.3M2021-06-15: 1.5M2021-06-30: 1.3M2021-07-15: 1.3M2021-07-30: 1.4M2021-08-13: 1.3M2021-08-31: 1.2M2021-09-15: 1.4M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.5M2021-11-15: 1.5M2021-11-30: 1.5M2021-12-15: 1.5M2022-01-14: 1.8M2022-01-31: 2.0M2022-02-15: 2.4M2022-02-28: 2.7M2022-03-15: 3.2M2022-03-31: 3.1M2022-04-14: 3.2M2022-04-29: 3.6M2022-05-13: 3.8M2022-05-31: 4.1M
the 31 May 2022 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Jun 2022

Praxis Precision Medicines had 2.9M shares sold short in the 15 Jun 2022 report, 2.0× the same report last year.

This period
2.9M (the 15 Jun 2022 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
249K
How far from its usual level
+3.7
Same report last year
1.5M
History used
593 days
2021-05-28: 1.3M2021-06-15: 1.5M2021-06-30: 1.3M2021-07-15: 1.3M2021-07-30: 1.4M2021-08-13: 1.3M2021-08-31: 1.2M2021-09-15: 1.4M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.5M2021-11-15: 1.5M2021-11-30: 1.5M2021-12-15: 1.5M2022-01-14: 1.8M2022-01-31: 2.0M2022-02-15: 2.4M2022-02-28: 2.7M2022-03-15: 3.2M2022-03-31: 3.1M2022-04-14: 3.2M2022-04-29: 3.6M2022-05-13: 3.8M2022-05-31: 4.1M2022-06-15: 2.9M
the 15 Jun 2022 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Jul 2022

Praxis Precision Medicines had 3.6M shares sold short in the 30 Jun 2022 report, 2.9× the same report last year.

This period
3.6M (the 30 Jun 2022 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
309K
How far from its usual level
+4.4
Same report last year
1.3M
History used
608 days
2021-06-15: 1.5M2021-06-30: 1.3M2021-07-15: 1.3M2021-07-30: 1.4M2021-08-13: 1.3M2021-08-31: 1.2M2021-09-15: 1.4M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.5M2021-11-15: 1.5M2021-11-30: 1.5M2021-12-15: 1.5M2022-01-14: 1.8M2022-01-31: 2.0M2022-02-15: 2.4M2022-02-28: 2.7M2022-03-15: 3.2M2022-03-31: 3.1M2022-04-14: 3.2M2022-04-29: 3.6M2022-05-13: 3.8M2022-05-31: 4.1M2022-06-15: 2.9M2022-06-30: 3.6M
the 30 Jun 2022 report24 earlier reportsnormal: 1.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026several at once

    reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year, while it saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year. Two unrelated kinds of activity within 27 days.

    See the evidence (3 changes)

    Lobbying: Lobbying on a new issue became public on 21 Oct 2026

    Praxis Precision Medicines lobbying on a new issue.

    New
    ['HCR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    9641691

    Lobbying: Lobbying spend jump became public on 21 Oct 2026

    Praxis Precision Medicines reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year.

    This period
    $160K (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $40K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +6.0
    Same quarter last year
    $40K
    History used
    1,279 days
    2024-09-30: $30K2024-12-31: $30K2025-03-31: $40K2025-06-30: $40K2025-09-30: $40K2025-12-31: $40K2026-03-31: $40K2026-06-30: $40K2026-09-30: $160K
    the quarter ended 30 Sep 20268 earlier quartersnormal: $40K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

    Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

    Praxis Precision Medicines saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year.

    This period
    70 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    32.5
    Typical spread (median absolute deviation)
    7
    How far from its usual level
    +3.6
    Same quarter last year
    26
    History used
    2,099 days
    2024-09-30: 282024-12-31: 322025-03-31: 332025-06-30: 252025-09-30: 262025-12-31: 932026-03-31: 682026-06-30: 552026-09-30: 70
    the quarter ended 30 Sep 20268 earlier quartersnormal: 32.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  2. 16 Nov 2026Institutional holdings change

    saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year.

    Same quarter last year: 26; its normal quarter is 32.5.

    See the evidence
    This period
    70 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    32.5
    Typical spread (median absolute deviation)
    7
    How far from its usual level
    +3.6
    Same quarter last year
    26
    History used
    2,099 days
    2024-09-30: 282024-12-31: 322025-03-31: 332025-06-30: 252025-09-30: 262025-12-31: 932026-03-31: 682026-06-30: 552026-09-30: 70
    the quarter ended 30 Sep 20268 earlier quartersnormal: 32.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  3. 21 Oct 2026Lobbying change

    reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year.

    Same quarter last year: $40K; its normal quarter is $40K.

    See the evidence
    This period
    $160K (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $40K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +6.0
    Same quarter last year
    $40K
    History used
    1,279 days
    2024-09-30: $30K2024-12-31: $30K2025-03-31: $40K2025-06-30: $40K2025-09-30: $40K2025-12-31: $40K2026-03-31: $40K2026-06-30: $40K2026-09-30: $160K
    the quarter ended 30 Sep 20268 earlier quartersnormal: $40K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  4. 21 Oct 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['HCR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    9641691
  5. 17 Aug 2026Lobbying record

    PRAXIS PRECISION MEDICINES, INC.: new lobbying registration (BALLARD PARTNERS) (dated 11 Jul 2026)

  6. 2 Jul 2026Filings record

    Changed its auditor

  7. 15 May 2026Institutional holdings change

    saw 68 13F filers open a new position in the quarter ended 31 Mar 2026, 2.1× the same quarter last year.

    Same quarter last year: 33; its normal quarter is 32.5.

    See the evidence
    This period
    68 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    32.5
    Typical spread (median absolute deviation)
    5.5
    How far from its usual level
    +4.4
    Same quarter last year
    33
    History used
    1,916 days
    2024-03-31: 562024-06-30: 352024-09-30: 282024-12-31: 322025-03-31: 332025-06-30: 252025-09-30: 262025-12-31: 932026-03-31: 68
    the quarter ended 31 Mar 20268 earlier quartersnormal: 32.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  8. 17 Feb 2026Institutional holdings change

    saw 93 13F filers open a new position in the quarter ended 31 Dec 2025, 2.9× the same quarter last year.

    Same quarter last year: 32; its normal quarter is 30.

    See the evidence
    This period
    93 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    30
    Typical spread (median absolute deviation)
    4.5
    How far from its usual level
    +9.4
    Same quarter last year
    32
    History used
    1,826 days
    2023-12-31: 72024-03-31: 562024-06-30: 352024-09-30: 282024-12-31: 322025-03-31: 332025-06-30: 252025-09-30: 262025-12-31: 93
    the quarter ended 31 Dec 20258 earlier quartersnormal: 30

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  9. 17 Feb 2026Institutional holdings record

    Orbis Allan Gray Ltd opened a $370.0M position (2025Q4 13F)

  10. 13 Jan 2026Short interest and volume change

    had 3.8M shares sold short in the 31 Dec 2025 report, 2.0× the same report last year.

    Same report last year: 1.9M; its normal report is 2.1M.

    See the evidence
    This period
    3.8M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    292K
    How far from its usual level
    +3.9
    Same report last year
    1.9M
    History used
    1,888 days
    2024-12-31: 1.9M2025-01-15: 2.0M2025-01-31: 2.6M2025-02-14: 2.7M2025-02-28: 1.8M2025-03-14: 2.1M2025-03-31: 2.0M2025-04-15: 1.8M2025-04-30: 1.8M2025-05-15: 1.9M2025-05-30: 1.8M2025-06-13: 1.7M2025-06-30: 1.8M2025-07-15: 1.9M2025-07-31: 2.1M2025-08-15: 2.3M2025-08-29: 2.4M2025-09-15: 2.4M2025-09-30: 2.6M2025-10-15: 2.6M2025-10-31: 3.1M2025-11-14: 3.6M2025-11-28: 3.6M2025-12-15: 3.7M2025-12-31: 3.8M
    the 31 Dec 2025 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 8 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 8 Jan 2026Filings record

    Director or officer change

  13. 25 Dec 2025Short interest and volume change

    had 3.7M shares sold short in the 15 Dec 2025 report, 2.4× the same report last year.

    Same report last year: 1.5M; its normal report is 2.1M.

    See the evidence
    This period
    3.7M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    279K
    How far from its usual level
    +3.9
    Same report last year
    1.5M
    History used
    1,872 days
    2024-12-13: 1.5M2024-12-31: 1.9M2025-01-15: 2.0M2025-01-31: 2.6M2025-02-14: 2.7M2025-02-28: 1.8M2025-03-14: 2.1M2025-03-31: 2.0M2025-04-15: 1.8M2025-04-30: 1.8M2025-05-15: 1.9M2025-05-30: 1.8M2025-06-13: 1.7M2025-06-30: 1.8M2025-07-15: 1.9M2025-07-31: 2.1M2025-08-15: 2.3M2025-08-29: 2.4M2025-09-15: 2.4M2025-09-30: 2.6M2025-10-15: 2.6M2025-10-31: 3.1M2025-11-14: 3.6M2025-11-28: 3.6M2025-12-15: 3.7M
    the 15 Dec 2025 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 10 Dec 2025Short interest and volume change

    had 3.6M shares sold short in the 28 Nov 2025 report, 2.4× the same report last year.

    Same report last year: 1.5M; its normal report is 2.0M.

    See the evidence
    This period
    3.6M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    256K
    How far from its usual level
    +4.1
    Same report last year
    1.5M
    History used
    1,855 days
    2024-11-29: 1.5M2024-12-13: 1.5M2024-12-31: 1.9M2025-01-15: 2.0M2025-01-31: 2.6M2025-02-14: 2.7M2025-02-28: 1.8M2025-03-14: 2.1M2025-03-31: 2.0M2025-04-15: 1.8M2025-04-30: 1.8M2025-05-15: 1.9M2025-05-30: 1.8M2025-06-13: 1.7M2025-06-30: 1.8M2025-07-15: 1.9M2025-07-31: 2.1M2025-08-15: 2.3M2025-08-29: 2.4M2025-09-15: 2.4M2025-09-30: 2.6M2025-10-15: 2.6M2025-10-31: 3.1M2025-11-14: 3.6M2025-11-28: 3.6M
    the 28 Nov 2025 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 26 Nov 2025Short interest and volume change

    had 3.6M shares sold short in the 14 Nov 2025 report, 2.4× the same report last year.

    Same report last year: 1.5M; its normal report is 2.0M.

    See the evidence
    This period
    3.6M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    206K
    How far from its usual level
    +5.4
    Same report last year
    1.5M
    History used
    1,841 days
    2024-11-15: 1.5M2024-11-29: 1.5M2024-12-13: 1.5M2024-12-31: 1.9M2025-01-15: 2.0M2025-01-31: 2.6M2025-02-14: 2.7M2025-02-28: 1.8M2025-03-14: 2.1M2025-03-31: 2.0M2025-04-15: 1.8M2025-04-30: 1.8M2025-05-15: 1.9M2025-05-30: 1.8M2025-06-13: 1.7M2025-06-30: 1.8M2025-07-15: 1.9M2025-07-31: 2.1M2025-08-15: 2.3M2025-08-29: 2.4M2025-09-15: 2.4M2025-09-30: 2.6M2025-10-15: 2.6M2025-10-31: 3.1M2025-11-14: 3.6M
    the 14 Nov 2025 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 13 Nov 2025Short interest and volume change

    had 3.1M shares sold short in the 31 Oct 2025 report, 1.8× the same report last year.

    Same report last year: 1.7M; its normal report is 1.9M.

    See the evidence
    This period
    3.1M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    188K
    How far from its usual level
    +4.1
    Same report last year
    1.7M
    History used
    1,827 days
    2024-10-31: 1.7M2024-11-15: 1.5M2024-11-29: 1.5M2024-12-13: 1.5M2024-12-31: 1.9M2025-01-15: 2.0M2025-01-31: 2.6M2025-02-14: 2.7M2025-02-28: 1.8M2025-03-14: 2.1M2025-03-31: 2.0M2025-04-15: 1.8M2025-04-30: 1.8M2025-05-15: 1.9M2025-05-30: 1.8M2025-06-13: 1.7M2025-06-30: 1.8M2025-07-15: 1.9M2025-07-31: 2.1M2025-08-15: 2.3M2025-08-29: 2.4M2025-09-15: 2.4M2025-09-30: 2.6M2025-10-15: 2.6M2025-10-31: 3.1M
    the 31 Oct 2025 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 10 Oct 2025Short interest and volume change

    had 2.6M shares sold short in the 30 Sep 2025 report, 1.5× the same report last year.

    Same report last year: 1.8M; its normal report is 1.9M.

    See the evidence
    This period
    2.6M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    143K
    How far from its usual level
    +3.6
    Same report last year
    1.8M
    History used
    1,796 days
    2024-09-30: 1.8M2024-10-15: 1.7M2024-10-31: 1.7M2024-11-15: 1.5M2024-11-29: 1.5M2024-12-13: 1.5M2024-12-31: 1.9M2025-01-15: 2.0M2025-01-31: 2.6M2025-02-14: 2.7M2025-02-28: 1.8M2025-03-14: 2.1M2025-03-31: 2.0M2025-04-15: 1.8M2025-04-30: 1.8M2025-05-15: 1.9M2025-05-30: 1.8M2025-06-13: 1.7M2025-06-30: 1.8M2025-07-15: 1.9M2025-07-31: 2.1M2025-08-15: 2.3M2025-08-29: 2.4M2025-09-15: 2.4M2025-09-30: 2.6M
    the 30 Sep 2025 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 15 Oct 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 15 Oct 2024Filings record

    Director or officer change

  20. 6 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 6 Jun 2024Filings record

    Director or officer change

  22. 15 May 2024Institutional holdings change

    saw 56 13F filers open a new position in the quarter ended 31 Mar 2024, 5.1× the same quarter last year.

    Same quarter last year: 11; its normal quarter is 14.

    See the evidence
    This period
    56 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    14
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +8.1
    Same quarter last year
    11
    History used
    1,186 days
    2022-03-31: 122022-06-30: 162022-09-30: 212022-12-31: 172023-03-31: 112023-06-30: 212023-09-30: 102023-12-31: 72024-03-31: 56
    the quarter ended 31 Mar 20248 earlier quartersnormal: 14

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  23. 11 Jan 2024Filings record

    A major agreement ended

  24. 11 Oct 2023Insiders record

    DeSimone Jill (director) bought 14,500 shares of PRAX ($25,375) (dated 10 Oct 2023)

  25. 28 Jun 2023Insiders record

    Souza Marcio (Chief Executive Officer) bought 10,000 shares of PRAX ($10,600) (dated 27 Jun 2023)

  26. 16 Jun 2023Filings record

    A major agreement ended

  27. 7 Apr 2023Insiders record

    Kelly Timothy Edwin (Chief Financial Officer) bought 8,000 shares of PRAX [amended] [same transaction as an earlier filing] (dated 6 Apr 2023)

  28. 28 Mar 2023Insiders change

    had 3 insiders buy $109K of its shares on the open market within 30 days (3 filings).

    Who bought: Mitchell Dean J, Souza Marcio, Kelly Timothy Edwin.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $109K
    Window
    26 Feb 2023 to 28 Mar 2023

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  29. 28 Mar 2023Insiders record

    Kelly Timothy Edwin (Chief Financial Officer) bought 8,000 shares of PRAX ($6,960) (dated 27 Mar 2023)

  30. 28 Mar 2023Insiders record

    Souza Marcio (Chief Executive Officer) bought 70,002 shares of PRAX ($60,202) (dated 27 Mar 2023)

  31. 28 Mar 2023Insiders record

    MITCHELL DEAN J (director) bought 50,000 shares of PRAX ($42,000) (dated 27 Mar 2023)

  32. 21 Mar 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 21 Mar 2023Filings record

    Director or officer change

  34. 15 Feb 2023Lobbying change

    registered for federal lobbying for the first time in our data (The Kpm Group Dc Llc).

    See the evidence (1 source record)
    Source coverage starts
    2 Jul 2009
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  35. 15 Feb 2023Lobbying record

    PRAXIS PRECISION MEDICINES: new lobbying registration (THE KPM GROUP DC LLC) (dated 1 Jan 2023)

  36. 12 Aug 2022Filings record

    Director or officer change

  37. 26 Jul 2022Filings record

    Director or officer change

  38. 13 Jul 2022Short interest and volume change

    had 3.6M shares sold short in the 30 Jun 2022 report, 2.9× the same report last year.

    Same report last year: 1.3M; its normal report is 1.6M.

    See the evidence
    This period
    3.6M (the 30 Jun 2022 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    309K
    How far from its usual level
    +4.4
    Same report last year
    1.3M
    History used
    608 days
    2021-06-15: 1.5M2021-06-30: 1.3M2021-07-15: 1.3M2021-07-30: 1.4M2021-08-13: 1.3M2021-08-31: 1.2M2021-09-15: 1.4M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.5M2021-11-15: 1.5M2021-11-30: 1.5M2021-12-15: 1.5M2022-01-14: 1.8M2022-01-31: 2.0M2022-02-15: 2.4M2022-02-28: 2.7M2022-03-15: 3.2M2022-03-31: 3.1M2022-04-14: 3.2M2022-04-29: 3.6M2022-05-13: 3.8M2022-05-31: 4.1M2022-06-15: 2.9M2022-06-30: 3.6M
    the 30 Jun 2022 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 28 Jun 2022Short interest and volume change

    had 2.9M shares sold short in the 15 Jun 2022 report, 2.0× the same report last year.

    Same report last year: 1.5M; its normal report is 1.5M.

    See the evidence
    This period
    2.9M (the 15 Jun 2022 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    249K
    How far from its usual level
    +3.7
    Same report last year
    1.5M
    History used
    593 days
    2021-05-28: 1.3M2021-06-15: 1.5M2021-06-30: 1.3M2021-07-15: 1.3M2021-07-30: 1.4M2021-08-13: 1.3M2021-08-31: 1.2M2021-09-15: 1.4M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.5M2021-11-15: 1.5M2021-11-30: 1.5M2021-12-15: 1.5M2022-01-14: 1.8M2022-01-31: 2.0M2022-02-15: 2.4M2022-02-28: 2.7M2022-03-15: 3.2M2022-03-31: 3.1M2022-04-14: 3.2M2022-04-29: 3.6M2022-05-13: 3.8M2022-05-31: 4.1M2022-06-15: 2.9M
    the 15 Jun 2022 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 22 Jun 2022Insiders record

    Mastrocola Lauren (Principal Accounting Officer) bought 3,000 shares of PRAX ($5,790) (dated 21 Jun 2022)

Showing the newest 40 of 76 entries; narrow the window or the kind of data to see older ones.

Not listed: 112 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001689548
Ticker
PRAX
Domain
praxismedicines.com
Employer name
Praxis Precision Medicines, Inc., Praxis Precision Medicines, Inc., f/k/a Epipm Therapeutics, Inc. (2 unverified)
Hq location
MA|BOSTON|02110 (1 unverified)
Lobbying client
praxis precision medicines
Name
Praxis Medicines International Holdings, LLC, Praxis Precision Medicines, Inc., Praxis Precision Medicines India Private Limited, Praxis Security Corporation
  • DOL H-1B labor condition applications and PERM certifications36 data points23 Aug 2021 to 13 Jul 2026
  • Federal lobbying disclosures (LDA)2 records, 45 data points1 Jan 2023 to 30 Sep 2026
  • SEC Form 13F institutional holdings2 records, 216 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)121 records10 Nov 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)432 data points31 Dec 2018 to 4 Nov 2026
  • SEC Form 4 insider transactions28 records, 84 data points10 Nov 2020 to 26 Jun 2026
  • FINRA short interest (twice monthly)431 data points30 Oct 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3064 data points16 Oct 2020 to 20 Nov 2026